p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy

PURPOSE: To conduct a Phase I trial of a Modified Vaccinia Ankara vaccine delivering wild type human p53 (p53MVA) in combination with gemcitabine chemotherapy in patients with platinum-resistant ovarian cancer. EXPERIMENTAL DESIGN: Patients received gemcitabine on days 1 and 8 and p53MVA vaccine on...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Hardwick, Nicola R, Frankel, Paul, Ruel, Christopher, Kilpatrick, Julie, Tsai, Weimin, Kos, Ferdynand, Kaltcheva, Teodora, Leong, Lucille, Morgan, Robert, Chung, Vincent, Tinsley, Raechelle, Eng, Melissa, Wilczynski, Sharon, Ellenhorn, Joshua D I, Diamond, Don J, Cristea, Mihaela
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5856606/
https://ncbi.nlm.nih.gov/pubmed/29301826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2709
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires